Neonatal diabetes and protein losing enteropathy: a case report by unknown
CASE REPORT Open Access
Neonatal diabetes and protein losing
enteropathy: a case report
Tamara McMillan1, Rose Girgis2 and Elizabeth A. C. Sellers1*
Abstract
Background: Neonatal diabetes is a rare form of monogenic diabetes with onset in the first six months of life
occurring in 1/100,000 to 1/400,000 births. Both permanent and transient forms have been described. Permanent
neonatal diabetes results predominantly from mutations in the KCNJ11 and ABCC8 genes. Less frequently, mutations of
the GATA6 gene, located on chromosome 18 cause a form of permanent neonatal diabetes resulting from pancreatic
hypoplasia or agenesis. Other anomalies associated with mutations of this gene have also been reported, most
commonly congenital heart disease.
Case presentation: We report the case of a Caucasian male infant diagnosed shortly after birth with neonatal
diabetes, truncus arteriosus type III, ventricular septal defect, atrial septal defect, an absent gallbladder and a right
inguinal hernia. His diabetes resulted from a de novo mutation of the GATA6 gene resulting in pancreatic hypoplasia.
At 20 months of age he developed protein losing enteropathy. This has not previously been associated with GATA6
mutations and it is not known if this association is causal.
Conclusion: The combination of neonatal diabetes and pancreatic agenesis/hypoplasia should alert the clinician to the
possibility of a GATA6 gene abnormality. The association of protein losing enteropathy is unique to the reported case.
Keywords: Neonatal diabetes, pancreatic hypoplasia, protein losing enteropathy
Background
Neonatal diabetes is a monogenic form of diabetes with
onset in the first 6 months of life. It occurs in 1 in
100,000 to 400,000 births [1]. Transient neonatal dia-
betes resolves within the first 18 months and predisposes
to the development of diabetes later in life [2]. The most
common underlying genetic causes of transient neonatal
diabetes are due to imprinting defects of chromosome 6
[2]. Permanent neonatal diabetes is predominantly due
to mutations in the KCNJ11 and ABCC8 genes which
encode for subunits of the sulfonylurea receptor. Perman-
ent neonatal diabetes can also be caused by mutations in
the insulin gene or the GCK gene which encodes for the
glucokinase enzyme [2].
Less commonly, neonatal diabetes results from pancre-
atic hypoplasia or agenesis. In a large study of 795 pa-
tients with neonatal diabetes, 39/795 (4.9 %) were found
to have pancreatic agenesis (defined by the need for both
insulin and having pancreatic exocrine insufficiency and
need for enzyme replacement therapy)[3]. Mutations of
PRX1 and PTF1A (found on chromosomes 13 and 10
respectively) are associated with pancreatic hypoplasia/
agenesis. These genes encode for transcription factors
required for pancreatic growth and development [4].
The GATA6 gene, on chromosome 18, has also been
linked to neonatal diabetes and is the most common cause
of pancreatic agenesis accounting for just over 50 % of
cases [3]. This gene encodes for GATA6, a transcription
factor involved in the development of multiple organ sys-
tems including the pancreas. Mutations of the GATA 6
gene may result in pancreatic hypoplasia or agenesis and
are associated with other anomalies, most commonly con-
genital heart disease [5]. GATA6 mutations account for
approx. 3 % of all cases of neonatal diabetes [3].
We report an infant presenting with neonatal diabetes
resulting from a de novo heterozygous mutation in the
GATA6 gene.
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Case presentation
A Caucasian male infant was born to a 33 year old
G7P5SA2 mother and her non-consanguineous partner
at 37 weeks gestation. The pregnancy was complicated
by morning sickness treated with Diclectin® (doxylamine
succinate/pyridoxine hydrochloride). There were no other
exposures to known teratogens. Intrauterine growth re-
striction was noted on ultrasound at 20 weeks gestation
(head circumference, weight, femur length all < 5%ile).
Oligohydramnios was noted at 34 weeks gestation, and
the mother was placed on bed rest.
Labour was induced at 37 weeks gestation for asym-
metric growth restriction. The infant was delivered by
caesarean section for failure to progress. Birth weight
was 1580 grams (<3rd %ile), length was 40 centimeters
(<3rd %ile) and head circumference was 31 centimeters
(3rd-10th %ile). Apgar scores were 9 and 9 at 1 and 5 mi-
nutes. Newborn examination revealed a small, non-
dysmorphic baby with minimal body fat, a heart murmur
and a right sided inguinal hernia.
Hyperglycemia was noted at 12 hours of age and an
insulin infusion was started. An echocardiogram identi-
fied truncus arteriosus type III, hypoplastic pulmonary
arteries, a ventricular septal defect and atrial septal de-
fect (VSD and ASD respectively). He underwent cardiac
repair on day 7 of life. Surgical repair involved the con-
struction of a right ventricular – pulmonary artery con-
duit, patch closure of the VSD and suture closure of the
ASD.
The pancreas was not identified on ultrasound. Ab-
dominal magnetic resonance imaging (MRI) demon-
strated minimal ectopic pancreatic tissue, absent gall
bladder, liver steatosis and normal kidneys and spleen.
Cerebral MRI was normal. C-peptide levels were un-
detectable, amylase and lipase were low and fecal fat was
elevated suggesting pancreatic endocrine and exocrine
deficiencies. Pancreatic exocrine replacement therapy
was started week 3 of life (Creon® pancrelipase delayed
release capsules 2500 u lipase/kg/d).
Family history revealed no history of cardiac or other
congenital abnormalities. The mother is known to be a
carrier of a balanced Robertsonian translocation (45, XX
der(13;14)(q11;q10). She had had two early miscarriages,
thought to be related to an unbalanced translocation.
The maternal aunt and grandfather have type 2 diabetes.
Our patient was found to carry the same balanced
Robertsonian translocation as his mother. Microarray
testing was normal. Based on the combination of a con-
genital heart defect and pancreatic agenesis, GATA6
gene mutation testing was performed. A frameshift dele-
tion in exon 2 (c744del) was found predicting a prema-
ture stop codon. Neither parent carries this mutation.
At four months of age the infant was transitioned from
a continuous insulin infusion to subcutaneous injections.
His course has been complicated by congenital hip dys-
plasia, developmental delay, and recurrent episodes of
bronchiolitis. At 22 months of age, the child presented
with facial edema, abdominal distension and poor feed-
ing. Serum albumin was 20 g/L (normal range 35-47 g/L
). Subsequent investigations revealed a normal urinalysis
and normal urine albumin. Testing for celiac disease was
negative. Upper endoscopy with video capsule placement
demonstrated diffuse erythema and superficial ulceration
of the stomach and edema throughout the small bowel.
Small bowel lymphangiectasia was also noted. Sigmoid-
oscopy to 20 cm did not demonstrate any abnormalities
of the colon. These findings lead to the diagnosis of pro-
tein losing enteropathy. Treatment with enoxaparin and
oral budesonide was initiated with good clinical
response.
At 30 months of age he weighs 11.59 kilograms (15th
%ile) and he has a height of 80 centimeters (<3rd %ile).
His diabetes is managed on a basal-bolus regime with in-
sulin glargine and lispro (diluted) for carbohydrate in-
take and correction. HbA1c is 7.4 % (normal 4-6 %).
Average total daily dose is 0.15 - 0.2 units/kg/day. His
low insulin requirements are thought to be due to en-
dogenous production of insulin by ectopic pancreatic tis-
sue identified on MRI. Fortunately, the child has not
experienced any episodes of severe hypoglycemia.
Conclusions
We report an infant presenting with neonatal diabetes
associated with congenital heart disease, absent gall
bladder and an inguinal hernia resulting from a de novo
heterozygous mutation in the GATA6 gene. The infant
has a number of associated anomalies including the
unique description of protein losing enteropathy.
In the largest published series of patients with a
GATA6 mutation, 24 probands and 5 parents were char-
acterised [3]. All but one patient, who was a mosaic mu-
tation carrier, developed diabetes. The majority had
permanent neonatal diabetes, but one had transient epi-
sodes of hyperglycemia and four developed diabetes be-
tween the ages of 12 and 46 years. In this same cohort,
93 % had evidence of high fecal fat or required pancre-
atic enzyme supplementation, 83 % had cardiac malfor-
mations, 24 % had hypothyroidism or hypopituitarism
and 38 % had neurocognitive deficits.
To the best of our knowledge, this is the first report of
a patient with a GATA6 mutation with pancreatic agene-
sis and congenital heart disease complicated by protein
losing enteropathy. Protein losing enteropathy is often
related to congenital heart defects associated with in-
creased right-sided pressures; however, our patient had
normal right sided heart pressures. If his protein losing
enteropathy is attributed to his heart defect, to our
knowledge, he is the first reported case secondary to
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truncus arteriousus. The GATA6 gene is known to be
involved in intestinal development [6]. Hepatobiliary
malformations and gut abnormalities (malrotation and
hernias) have been reported [3, 5]. This suggests the
possibility that the protein losing enteropathy in our pa-
tient is related to his gene mutation.
We report a case of neonatal diabetes resulting from a
de novo mutation of the GATA6 gene resulting in pan-
creatic hypoplasia. Our case has several associated
anomalies including truncus arteriosus, gallbladder agen-
esis, an inguinal hernia and uniquely, protein losing en-
teropathy illustrating the variable phenotype associated
with mutations of this gene. Although uncommon, it is
important to consider GATA6 mutations and investigate
for pancreatic agenesis/hypoplasia if neonatal diabetes is
seen in combination with congenital heart defects or
other anomalies. Given the variability in phenotype, par-
ents should be screened for carrier status. Carriers may
benefit from early screening for diabetes as age of pres-
entation varies significantly. The combination of neo-
natal diabetes and other congenital anomalies should
alert the clinician to the possibility of a GATA6 gene
abnormality.
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